Metformin Therapy Center

Study confirms recent guideline changes on metformin use in moderate-to-severe chronic kidney disease.

Long-term impact of intrauterine exposure to medication on the offspring remains unclear.

Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.

Determining which patients benefit most from lifestyle, metformin interventions may improve individualized care decisions.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.

The results of the REMOVAL study were presented at the 2017 European Association for the Study of Diabetes (EASD) in Lisbon

The evolution of metformin therapy through the decades.

Study prompts more concerns for future seniors with diabetes.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Study focused on type 2 diabetes patients who initiate metformin.